文献速递胃肠动力与功能性疾病

系统综述与Meta分析:薄荷油治疗肠易激综合征的疗效

Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome.
PubMed 文献 · Aliment Pharmacol Ther · 2022-08-09

该系统综述与Meta分析共纳入10项随机对照试验(1030例患者),评估薄荷油治疗肠易激综合征的疗效与安全性。薄荷油在改善整体肠易激综合征症状和腹痛方面优于安慰剂,但不良事件发生率显著更高,证据质量极低。作者认为需要足够把握度的随机对照试验验证其作为一线治疗的价值。

要点

  • 薄荷油改善整体肠易激综合征症状优于安慰剂(RR不改善=0.65,95%CI 0.43-0.98,NNT=4)。
  • 薄荷油改善腹痛优于安慰剂(RR腹痛不改善=0.76,95%CI 0.62-0.93,NNT=7)。
  • 薄荷油不良事件发生率显著高于安慰剂(RR=1.57,95%CI 1.04-2.37),证据质量极低。

核心结论

  • 薄荷油在治疗肠易激综合征方面优于安慰剂,但不良事件更频繁,证据质量极低。
  • 需要足够把握度的随机对照试验验证薄荷油作为肠易激综合征一线治疗的价值。

研究设计与样本

  • 检索截至2022年4月2日的医学文献,纳入薄荷油治疗肠易激综合征的随机对照试验(RCT)。
  • 共纳入10项符合条件的随机对照试验,合计1030例患者。
  • 疗效与安全性采用二分类评估,数据用随机效应模型合并,报告为合并相对危险度(RR)及95%置信区间(CI)。

主要发现

  • 薄荷油改善整体肠易激综合征症状优于安慰剂:不改善的RR=0.65(95%CI 0.43-0.98),NNT=4(95%CI 2.5-71)。
  • 薄荷油改善腹痛优于安慰剂:腹痛不改善的RR=0.76(95%CI 0.62-0.93),NNT=7(95%CI 4-24)。
  • 薄荷油组任何不良事件发生率显著高于安慰剂组:RR=1.57(95%CI 1.04-2.37)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 证据质量极低。
  • 需要足够把握度的随机对照试验验证薄荷油作为肠易激综合征一线治疗的价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Irritable bowel syndrome (IBS) is one of the most common disorders of gut-brain interaction, with a complex pathophysiology. Antispasmodics are prescribed as first-line therapy because of their action on gut dysmotility. In this regard, peppermint oil also has antispasmodic properties. AIM: To update our previous meta-analysis to assess efficacy and safety of peppermint oil, particularly as recent studies have cast doubt on its role in the treatment of IBS METHODS: We searched the medical literature up to 2nd April 2022 to identify randomised controlled trials (RCTs) of peppermint oil in IBS. Efficacy and safety were judged using dichotomous assessments of effect on global IBS symptoms or abdominal pain, and occurrence of any adverse event or of gastro-oesophageal reflux. Data were pooled using a random effects model, with efficacy and safety reported as pooled relative risks (RRs) with 95% confidence intervals (CIs). RESULTS: We identified 10 eligible RCTs (1030 patients). Peppermint oil was more efficacious than placebo for global IBS symptoms (RR of not improving = 0.65; 95% CI 0.43-0.98, number needed to treat [NNT] = 4; 95% CI 2.5-71), and abdominal pain (RR of abdominal pain not improving = 0.76; 95% CI 0.62-0.93, NNT = 7; 95% CI 4-24). Adverse event rates were significantly higher with peppermint oil (RR of any adverse event = 1.57; 95% CI 1.04-2.37). CONCLUSIONS: Peppermint oil was superior to placebo for the treatment of IBS, but adverse events were more frequent, and quality of evidence was very low. Adequately powered RCTs of peppermint oil as first-line treatment for IBS are needed.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ingrosso MR, Ianiro G, Nee J, et al. Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome. Aliment Pharmacol Ther. 2022. PMID: 35942669. doi:10.1111/apt.17179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。